

## PRONOMZ VENTURES LLP

Regd. Office: Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 | Fax: +91 80 4657 0400 | E-mail: info@agnus.in | www.agnus.in | LLPIN: AAA-3757

#### 28 September 2020

To

BSE Limited
Phiroze Jeejeebhoy Towers,

Dalal Street,

Scrip code: 532531

Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza,

Bandra Kurla Complex,

Bandra (E), Mumbai - 400 051

Scrip code: STAR

Ms. Manjula Ramamurthy Company Secretary & Compliance Officer Strides Pharma Science Ltd 201, Devavrata, Sector 17, Vashi, Navi Mumbai- 400703.

Dear Sir/ Madam,

Sub: Disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 - Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a)(ii)

Further to our intimation dated 19<sup>th</sup> September 2020 under regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SAST Regulations), please find enclosed the form as prescribed under Regulation 10(6) of the SEBI SAST Regulations setting out the details of the acquisition of shares of Strides Pharma Science Ltd done inter-se among promoters in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011 and there is no change in promoter holding consequent to such transfer.

Kindly take the same on record.

Thanking you, Yours faithfully,

For and on behalf of M/s Pronomz Ventures LLP

Promoter Group Entity of Strides Pharma Science Ltd]

**Designated Partner** 

Encl.: A/a



### PRONOMZ VENTURES LLP

Regd. Office: Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 | Fax: +91 80 4657 0400 | E-mail: info@agnus.in | www.agnus.in | LLPIN: AAA-3757

# <u>Disclosures under Regulation 10(6) Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011</u>

1.	Name of t	he Target Company (TC)	Strides Pharma Science Ltd			
2.	Name of t	he acquirer(s)	Pronomz Ventures LLP			
3.	Name of t	he stock exchange where	BSE Limited ('BSE') and National Stock Exchange of India			
	shares of the TC are listed		Limited ('NSE')			
4.	Details of the transaction including		Sale of shares by Sequent Scientific Limited ('Sequent') in Stride			
	rationale, if any, for the transfer/		Pharma Science Ltd through inter-se promoter transfer t			
	acquisition of shares		Pronomz Ventures LLP			
5.	Relevant regulation under which the acquirer		Regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares			
	is exempted from making open offer		and Takeovers) Regula	tions, 2011		
6.	· · · ·		Yes			
	was required to be made under regulation 10					
	(5) and if so,					
	- whether disclosure was made and					
	whether it was made within the timeline					
	<ul><li>specified under the regulations.</li><li>date of filing with the stock exchange</li></ul>					
	- date of filling with the stock exchange					
7.	Details of acquisition		Disclosures required to be		Whether the	
			made under		disclosures under	
			regulation 10(5)		regulation 10(5)	
					are actually made	
	a.	Name of the transferor / seller	Sequent Scientific Limited		Yes	
	b.	Date of acquisition	25 <sup>th</sup> September 2020		Yes	
	c.	Number of shares/ voting rights	Name of person	No of Equity	Yes	
		in respect of the acquisitions		Shares		
		from each	Sequent Scientific	3.70%		
		person mentioned in 7(a) above	Limited			
	d. Total shares <del>proposed to be acquired</del> / actually acquired as a		3.70%		Yes	
		% of diluted share capital of TC				
	Defendant in the					
			Rs. 475 per share			
	e.	Price at which shares are	Ns. 475 per s			
	e.	proposed to  be acquired / actually acquired	N3. 473 per 3			



### PRONOMZ VENTURES LLP

Regd. Office: Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 | Fax: +91 80 4657 0400 | E-mail: info@agnus.in | www.agnus.in | LLPIN: AAA-3757

8.	Shareholding details		Pre-Transaction		Post-Transaction	
			No. of shares	% w.r.t total share	No. of	% w.r.t
			held	capital of TC	shares	total
					held	share
						capital
						of TC
	A	Acquirer(s) and PACs (other than sellers)(*)	75			
	(i)	Pronomz Ventures LLP	1,26,65,000	14.13%	1,59,77,500	17.83%
	(,		1,20,03,000	111370	1,33,77,300	17.0370
	В	Seller (s)				
	(i)	Sequent Scientific Limited	33,12,500	3.70%	÷	0.00%

(\*) Shareholding of each entity shall be shown separately and then collectively in a group.

The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

Signature:

Name: Pudhucode Radhakrishnan Kannan

(Designated Partner)

Date: Bengaluru

Place: 28 September 2020

### Arun Kumar Family Office increase its holding in Strides by 4.37%

Purchases 3.31 million shares from SeQuent and 600,000 shares from Shasun family

The family office of Arun Kumar, founder and non-executive Chairman of Strides Pharma Science Limited ("Strides" or "Company") would like to update that it has completed the purchase of 3.31 million shares (3.70% of Total Outstanding Shares) of Strides held by SeQuent Scientific Limited ("SeQuent") for an aggregate consideration of ₹1,573 million. The transaction was duly approved by the Shareholders of SeQuent on Sep 19, 2020.

Further, on Sep 11, 2020, the Family Office of Arun Kumar also purchased 600,000 shares (0.67% of the total outstanding shares) of Strides from the Shasun family who are also promoters in the Company.

The information has been shared with the Company and its stakeholders for prudent disclosures.